These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 10093705

  • 1. DNA gyrase as a drug target.
    Maxwell A.
    Biochem Soc Trans; 1999 Feb; 27(2):48-53. PubMed ID: 10093705
    [No Abstract] [Full Text] [Related]

  • 2. High frequency of mutations at codon 83 of the gyrA gene of quinolone-resistant clinical isolates of Escherichia coli.
    Ruiz J, Marco F, Goñi P, Gallardo F, Mensa J, Trilla A, Jimenez de Anta T, Vila J.
    J Antimicrob Chemother; 1995 Oct; 36(4):737-8. PubMed ID: 8591951
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.
    Yoshida H, Bogaki M, Nakamura M, Nakamura S.
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1271-2. PubMed ID: 2168148
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.
    Schedletzky H, Wiedemann B, Heisig P.
    J Antimicrob Chemother; 1999 May; 43 Suppl B():31-7. PubMed ID: 10382873
    [Abstract] [Full Text] [Related]

  • 9. Analysis of the NH2-terminal 83rd amino acid of Escherichia coli GyrA in quinolone-resistance.
    Yonezawa M, Takahata M, Banzawa N, Matsubara N, Watanabe Y, Narita H.
    Microbiol Immunol; 1995 May; 39(4):243-7. PubMed ID: 7651238
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clerocidin, a terpenoid antibiotic, inhibits bacterial DNA gyrase.
    McCullough JE, Muller MT, Howells AJ, Maxwell A, O'Sullivan J, Summerill RS, Parker WL, Wells JS, Bonner DP, Fernandes PB.
    J Antibiot (Tokyo); 1993 Mar; 46(3):526-30. PubMed ID: 8386713
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Mechanisms of bacterial resistance to quinolones].
    Yoshida H.
    Nihon Saikingaku Zasshi; 1996 Oct; 51(4):973-92. PubMed ID: 8994343
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.
    Zhao X, Xu C, Domagala J, Drlica K.
    Proc Natl Acad Sci U S A; 1997 Dec 09; 94(25):13991-6. PubMed ID: 9391140
    [Abstract] [Full Text] [Related]

  • 20. Bacterial resistance to quinolones: mechanisms and clinical importance.
    Wolfson JS, Hooper DC.
    Rev Infect Dis; 1989 Dec 09; 11 Suppl 5():S960-8. PubMed ID: 2549610
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.